Trinity Biotech ( (TRIB) ) just unveiled an update.
On March 13, 2025, Trinity Biotech announced a significant step in its transformation plan by appointing Barclays Capital Inc. as its exclusive financial advisor to support its strategic realignment, focusing on continuous glucose monitoring (CGM) technology. This move reflects the company’s commitment to CGM as its primary strategic focus, aiming to drive profitability and optimize its business portfolio. The CEO highlighted the strong clinical trial data and market interest in their CGM solution, indicating a promising opportunity for growth and improved financial prospects.
More about Trinity Biotech
Trinity Biotech is a commercial-stage biotechnology company specializing in diabetes management solutions and human diagnostics, including wearable biosensors. The company develops, acquires, manufactures, and markets diagnostic systems for the point-of-care and clinical laboratory segments. Recently, it has entered the wearable biosensor industry with the acquisition of Waveform Technologies Inc.’s biosensor assets, aiming to develop a range of biosensor devices, starting with a continuous glucose monitoring product. Trinity Biotech operates directly in the United States and through international distributors in over 75 countries.
YTD Price Performance: -28.53%
Average Trading Volume: 2,310,881
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.39M
For a thorough assessment of TRIB stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com